Study S000071

A Phase 3, Randomized, Open Label Trial Comparing Efficacy and Safety of BGM0504 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Patients With Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07064486
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 152
Start: 2025-07-04
Primary completion: 2027-04-30
Lead sponsor: BrightGene Bio-Medical Technology Co., Ltd.
Conditions: Type 2 Diabetes (T2DM)
Interventions: DRUG:BGM0504; DRUG:Semaglutide
Results posted: FALSE

Registered primary outcomes

Change From Baseline in Hemoglobin A1c (HbA1c) [Week 0 to Week 24]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.